anti-O-linked glycan/undisclosed target T-cell engager GlyTR technology (GlyTR therapeutics)

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug Nameanti-O-linked glycan/undisclosed target T-cell engager GlyTR technology (GlyTR therapeutics)
Drug Alias NameGlyTRTM immunotherapy (University of California Irvine)Glycan dependent T cell engager immunotherapy (University of California Irvine)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant proteinBiologics > T cell engagers
Mechanisms of ActionImmunostimulantsT lymphocytes stimulants
TargetsUpdating
Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity of California Irvine
China Registration ClassN/A

Develop Information

Active CompaniesGlyTR Therapeutics Inc
Inactive CompaniesUniversity of California IrvineUniversity Of California
Active IndicationsSolid tumoursHematologic Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A